Belgium's Galapagos signs deal with U.S. group Biogen

BRUSSELS Tue Nov 12, 2013 2:01am EST

BRUSSELS Nov 12 (Reuters) - Belgian biotech group Galapagos said its unit Biofocus signed a 3-year research deal with U.S. firm Biogen Idec to find new treatments for scleroderma.

The total value of the deal, which includes an upfront sum as well as further milestone payments, could reach $31 million, Galapagos said.

Scleroderma is a disease that involves the buildup of scar-like tissue in the skin.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.